Skip to content
Toggle main navigation
MPN World logo
MPN World logo
  • Home
  • Description how to move to the new MPN World.
  • What is MPN World?
  • Benefits of Joining
  • How to Join?
  • FAQs
    Log in
    Select an available language
    EN

    The latest MPN-News

    from all over the world.

     

    Picked from reliable sources by our redaction

    (Language is English)

    All
    01 ET Clinical trials
    02 PV Clinical trials
    03 MF Clinical trials
    04 Basic information about MPNs / Basisinformatie over MPN's / Información básica sobre las MPN
    05 Diagnosed with MPNs / Gediagnosticeerd met MPN's / Diagnosticados con MPN
    06 Living with MPNs / Leven met MPN's / Viviendo con MPN
    07 Women and pregnancy / Vrouwen en zwangerschap / Mujeres y embarazo
    20 Medication/ Medicatie/ Medicación
    70 Research/ Onderzoek /Investigación

    Results (3)

    Nuevo posible tratamiento para la Policitemia Vera (PV)

    Nuevo posible tratamiento para la Policitemia Vera (PV)

    El pasado 20 de mayo, MPN España organizó un webinar con la participación de Silence Therapeutics, una empresa biotecnológica del Reino Unido que investiga terapias basadas en ARN para la Policitemia Vera (PV).Durante la sesión, Alberto Martínez, Director Clínico de Silence, presentó Divesiran, una terapia en investigación que utiliza interferencia por ARN para bloquear la expresión genética anorm
    July 4, 2025
    Pegasys® Is Back in Europe: EMA Approves New Manufacturing Site

    Pegasys® Is Back in Europe: EMA Approves New Manufacturing Site

    Good news for patients with Myeloproliferative Neoplasms (MPNs): Pegasys® is being replenished across Europe following a key regulatory approval.On April 25, 2025, the European Medicines Agency (EMA) officially approved Loba biotech GmbH, a wholly owned manufacturing subsidiary of pharma& GmbH, as an authorized production site for the active pharmaceutical ingredient (API) peginterferon alfa-2a, t
    May 8, 2025
    Understanding Allele Burden in MPNs

    Understanding Allele Burden in MPNs

    The 4th MPN Spring Symposium provided a unique opportunity for healthcare professionals and researchers to delve into the complexities of Myeloproliferative Neoplasms (MPNs) and the critical role of allele burden in treatment management. During this symposium, we had the privilege to hear from several esteemed MPN experts who shared their insights and research on the subject.Insights from MPN Expe
    September 30, 2024
    Contact
    Global MPN Scientific Foundation
    Avenida Josep Tarradellas 157, 5o 2a - Barcelona, 08029 - Spain
    info@gmpnsf.org
    Links
    • Terms of Use
    • About Global MPNSF
    • Privacy Policy
    Cookies
    Reselect cookie settings
    Community engagement platform by Hivebrite.